Deploying its own resources and integrating its patented technology, which separates cancer cells from the blood sample, with other downstream analytical platforms,    Biolidics aims to obtain the clinical validation of its proprietary cancer diagnostic solutions in the second half of 2020.

   

After which, the Group will launch and progressively market the cancer diagnostic solutions to hospitals across China. As of February 2019, there had been a total of 33,000 hospitals in China.

   

With increasing incidence and mortality, cancer is the leading cause of death in China and it has become a major public health problem. Cancer generally requires long periods of treatment and as patients undergo cancer drug treatments, there is a need to monitor the effectiveness of the treatment throughout the various stages of a patient' s cancer journey, such as cancer screening, cancer staging and post-cancer monitoring.

   

With a growing demand for minimally invasive procedures in cancer diagnostics, Biolidics& rsquo solutions, which uses blood sample from patients, aims to provide cancer patients in China with accurate, cost-effective, and real-time diagnoses to improve their treatment outcomes and quality of life.